Sangel Capital
Asia, Guangdong, China, Shenzhen'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)
Description
one of the earliest globally operating professional biomedical venture capital institutions in China
Investor Profile
Sangel Capital has backed more than 6 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 3 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series B, Series C, Series A rounds (top funding stages).
- Majority of deals are located in United States, Canada.
- Strong thematic focus on Biotechnology, Health Care, Pharmaceutical.
Stage Focus
- Series B (50%)
- Series C (33%)
- Series A (17%)
Country Focus
- United States (83%)
- Canada (17%)
Industry Focus
- Biotechnology
- Health Care
- Pharmaceutical
- Biopharma
- Medical
- Medical Device
- Genetics
- Therapeutics
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
Who does Sangel Capital frequently co-invest with?
What are some of recent deals done by Sangel Capital?
Find More Investors Like Sangel Capital
Discover similar investors in our database and build your perfect investor list.
Need help with your fundraising strategy?Read our fundraising guides
